
Insulet (PODD) Stock Forecast & Price Target
Insulet (PODD) Analyst Ratings
Bulls say
Insulet has demonstrated a significant opportunity in the insulin pump market, bolstered by its innovative Omnipod system, which offers a user-friendly mobile-operated device that has gained traction with approximately 500,000 users since its FDA approval in 2005. The company's ongoing emphasis on improving gross margins and leveraging its business model is expected to enhance operational income and earnings per share (EPS), supported by projections of operating margin expansion in the coming years. Insulet's strong positioning, characterized by its differentiated product offering and first-mover advantage in the Type 2 diabetes market, presents a favorable outlook for sustained growth in a competitive industry.
Bears say
The projected operating income for Insulet in 2026 has been revised downward to $549.3 million, reflecting a decrease from the previously estimated $561.0 million, alongside a reduction in earnings per share (EPS) expectations to $5.74 from $6.09. The company faces potential competitive pressures if rival products are introduced to the market before Insulet can secure its position within the diabetes management community, which may hinder its ability to meet future performance expectations. Additionally, a consistent reduction in cost of goods sold (COGS) is essential for sustaining its business model, highlighting ongoing financial challenges that could negatively impact profitability.
This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.
Insulet (PODD) Analyst Forecast & Price Prediction
Start investing in Insulet (PODD)
Order type
Buy in
Order amount
Est. shares
0 shares